Be aware of misdiagnosis tied to COVID-19 focusing: a case report of abciximab-induced alveolar haemorrhage thought to be SARS-CoV-2 in a patient with ST-segment elevation myocardial infarction.

Abciximab-induced alveolar hemorrhage treated with rescue extracorporeal membranous oxygenation.

Pulmonary hemorrhage and acute pulmonary thromboembolism after abciximab administration.

A retrospective analysis and case series of glycoprotein IIb/IIIa inhibitor associated diffuse alveolar hemorrhage: two case reports.

Abciximab-induced alveolar hemorrhage after percutaneous coronary intervention.

A case report of alveolar haemorrhage associated with severe thrombocytopenia induced by abciximab infusion in a patient with an acute coronary syndrome.

Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors.

Abciximab and fatal pulmonary hemorrhage.

Fatal pulmonary haemorrhage with the combined use of abciximab and fibrinolytic agent.

Pulmonary hemorrhage after percutaneous coronary intervention with abciximab therapy.

Alveolar hemorrhage as a complication of treatment with abciximab.

Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.

Fatal alveolar hemorrhage and Abciximab (ReoPro) therapy for acute myocardial infarction.